6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $319M | -$289M | 11.9% | -77.0% | 30.0% | -12.3% | -$451M | $1.1B | $311M |
| 2024 | $511M | -$1.4B | 23.7% | -27.8% | 152.5% | -97.4% | -$52M | — | $836M |
| 2023 | $502M | -$246M | 24.6% | 1.8% | 41.3% | -34.6% | $49M | — | $50M |
| 2022 | $640M | -$2.1B | 1.3% | -329.5% | 524.3% | -265.7% | -$179M | — | $16M |
| 2021 | $544M | $47M | 43.9% | 24.2% | 3.5% | 1.9% | -$57M | — | $118M |
| 2020 | $60M | -$12M | 15.6% | -10.5% | -13.7% | -81373.3% | -$24M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $164M | -$1.2B | 42.7% | -47.8% | 47.8% | -22.0% | -$584M | $4.3B | $1.8B |
| Mar '26 | $115M | -$347M | 26.1% | -269.4% | 26.6% | -11.3% | -$139M | $2.1B | $1.0B |
| Dec '25 | $80M | $214M | 26.0% | -149.5% | -22.2% | 9.1% | -$122M | $1.1B | $311M |
| Sep '25 | $81M | -$144M | 4.8% | -67.6% | 11.5% | -6.6% | -$113M | — | $453M |
| Jun '25 | $79M | -$937M | 6.4% | -33.4% | 78.6% | -50.6% | -$87M | — | $581M |
| Mar '25 | $80M | $576M | 10.3% | -59.1% | -186.6% | 38.5% | -$129M | — | $698M |
| Dec '24 | $95M | -$388M | 5.0% | -171.3% | 41.2% | -26.3% | -$15M | — | $836M |
| Sep '24 | $95M | -$455M | -0.2% | -43.2% | 55.1% | -55.2% | -$25M | — | $253M |
| Jun '24 | $141M | -$902M | 27.5% | -64.3% | 76.4% | -135.8% | -$2M | — | $96M |
| Mar '24 | $179M | $211M | 43.3% | 30.8% | -66.1% | 25.9% | -$10M | — | $98M |
| Dec '23 | $142M | -$196M | 27.7% | 2.8% | 32.8% | -27.5% | $10M | — | $50M |
| Sep '23 | $113M | -$41M | 13.7% | -10.7% | 9.8% | -5.8% | $3M | — | $42M |
| Jun '23 | $127M | -$9M | 29.1% | 7.5% | 2.4% | -1.2% | $18M | — | $58M |
| Mar '23 | $121M | -$388000 | 26.3% | 6.3% | 0.1% | -0.1% | $18M | — | $47M |
| Dec '22 | $121M | -$435M | -39.0% | -524.6% | 106.2% | -53.8% | -$24M | — | $16M |
| Sep '22 | $163M | -$435M | -16.7% | -246.9% | -595.4% | -31.0% | -$57M | — | $30M |
| Jun '22 | $164M | -$810M | 7.8% | -637.5% | -194.6% | -43.9% | $40M | — | $129M |
| Mar '22 | $193M | -$466M | 36.4% | -13.9% | -41.4% | -17.2% | -$137M | — | $96M |
| Dec '21 | $302M | -$13M | 46.8% | -0.3% | -1.0% | -0.5% | $115M | — | $118M |
| Sep '21 | $113M | -$19M | 51.6% | -2.2% | -1.5% | -5.4% | -$77M | — | $2M |
How the market has priced CORZ against its own fundamentals since 2024-01 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Core Scientific's revenue has grown 39.5% per year. These are computed facts, not advice.
As of FY2025, Core Scientific reported $1.1B of total debt against $311M of cash.
In FY2025, gross margin was 11.9%, operating margin -77.0%, and net margin -90.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.